196 related articles for article (PubMed ID: 31672856)
1. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
3. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
Hoshimoto S; Faries MB; Morton DL; Shingai T; Kuo C; Wang HJ; Elashoff R; Mozzillo N; Kelley MC; Thompson JF; Lee JE; Hoon DS
Ann Surg; 2012 Feb; 255(2):357-62. PubMed ID: 22202581
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
[TBL] [Abstract][Full Text] [Related]
5. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
6. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
Kitago M; Koyanagi K; Nakamura T; Goto Y; Faries M; O'Day SJ; Morton DL; Ferrone S; Hoon DS
Clin Chem; 2009 Apr; 55(4):757-64. PubMed ID: 19233913
[TBL] [Abstract][Full Text] [Related]
7. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
[TBL] [Abstract][Full Text] [Related]
8. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
[TBL] [Abstract][Full Text] [Related]
9. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
[TBL] [Abstract][Full Text] [Related]
10. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Thiel E; Foerster MH; Keilholz U
Oncology; 2011; 80(1-2):57-62. PubMed ID: 21625180
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
13. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
14. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
16. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
17. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; RamÃrez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
[TBL] [Abstract][Full Text] [Related]
18. A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells.
Xu MJ; Cooke M; Steinmetz D; Karakousis G; Saxena D; Bartlett E; Xu X; Hahn SM; Dorsey JF; Kao GD
PLoS One; 2015; 10(3):e0123376. PubMed ID: 25807549
[TBL] [Abstract][Full Text] [Related]
19. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
Li J; Fu W; Zhang W; Li P
Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.
Lucci A; Hall CS; Patel SP; Narendran B; Bauldry JB; Royal RE; Karhade M; Upshaw JR; Wargo JA; Glitza IC; Wong MKK; Amaria RN; Tawbi HA; Diab A; Davies MA; Gershenwald JE; Lee JE; Hwu P; Ross MI
Clin Cancer Res; 2020 Apr; 26(8):1886-1895. PubMed ID: 32015020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
